

Special Issue

Epilepsy: Pathogenesis, Treatment, and Precision Medicine

Message from the Guest Editor


Epilepsy is a chronic disabling neurological disorder that affects people of all ages. Most concern is that over 30% of people with epilepsy will fail medication, so-called **medically intractable** or **drug-resistant**, which will be the focus of this special issue. Individuals with medically intractable seizures have reduced quality of life due to stigma, loss of independence, the cognitive side effects of medication, and recurring seizures. Additionally, the mortality of intractable epilepsy is over 4 times that of age-matched controls. Individuals with medically intractable epilepsy should be evaluated in a comprehensive epilepsy program. Appropriate characterization of epilepsy can improve seizure control as well as identify surgical candidates. In many cases, **surgery** can cure this chronic, disabling, and often deadly neurological disease. Cure from epilepsy significantly elevates the quality of life and erases the increased mortality risk. In this special issue of the JPM, the topics of pathogenesis, treatment, and precision medicine of **medically intractable epilepsy** will be explored. Both original research and review articles are welcome.

Guest Editor

Prof. Dr. Warren W. Boling
Department of Neurosurgery, Loma Linda University Health, Loma Linda, CA 92354, USA

Deadline for manuscript submissions

closed (15 April 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/117300

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).